From Alphastreet - Earnings Decoded. Market Intelligence Delivered · Newsdesk · · 1m 10s
Eli Lilly Q2 2026 Revenue Surge
Lilly's Mounjaro revenue nearly doubled to $9.94 billion in Q2 2026, driving 48% revenue growth.
In brief
Lilly's Mounjaro revenue nearly doubled to $9.94 billion in Q2 2026, driving 48% revenue growth. Eli Lilly reported $23 billion in Q2 2026 revenue, with Mounjaro contributing $9.94 billion, a 91% year-over-year increase. Originally reported by Alphastreet - Earnings Decoded. Market Intelligence Delivered.
Q2 2026 Results
Eli Lilly reported non-GAAP earnings per share of $8.38, exceeding consensus estimates of $6.58.
Mounjaro Revenue Surge
Mounjaro revenue nearly doubled to $9.94 billion in Q2 2026, a 91% year-over-year increase.
Market Share Leadership
Mounjaro now constitutes approximately 43% of total quarterly revenue, cementing its role as the growth engine.
Zepbound and Foundayo Impact
Zepbound contributed to revenue acceleration, while Foundayo, Lilly's April 2026 oral obesity pill, marked its first full reporting period.
Full-Year Guidance Raising
Lilly raised full-year 2026 revenue guidance to $85.0 billion to $87.0 billion, up from $82.0 billion to $85.0 billion.
Geographic Pricing Shift
International Mounjaro sales jumped 172% year-over-year to $5.14 billion, while U.S. sales reached $4.8 billion.
Pricing and Margin Dynamics
International Mounjaro sales saw a 36% price decline amid volume growth, reflecting competitive pressure and healthcare cost containment.
The short version
Eli Lilly reported $23 billion in Q2 2026 revenue, with Mounjaro contributing $9.94 billion, a 91% year-over-year increase.
